SI0984788T1 - Pharmaceutical compositions of peptides having low solubility in physiological medium - Google Patents

Pharmaceutical compositions of peptides having low solubility in physiological medium

Info

Publication number
SI0984788T1
SI0984788T1 SI9830555T SI9830555T SI0984788T1 SI 0984788 T1 SI0984788 T1 SI 0984788T1 SI 9830555 T SI9830555 T SI 9830555T SI 9830555 T SI9830555 T SI 9830555T SI 0984788 T1 SI0984788 T1 SI 0984788T1
Authority
SI
Slovenia
Prior art keywords
peptides
pharmaceutical compositions
low solubility
physiological medium
physiological
Prior art date
Application number
SI9830555T
Other languages
English (en)
Slovenian (sl)
Inventor
Peter Richardson
Original Assignee
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP97108593A external-priority patent/EP0880968A1/de
Application filed by Applied Research Systems Ars Holding N.V. filed Critical Applied Research Systems Ars Holding N.V.
Publication of SI0984788T1 publication Critical patent/SI0984788T1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/25Growth hormone-releasing factor [GH-RF] (Somatoliberin)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/09Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
SI9830555T 1997-05-28 1998-05-26 Pharmaceutical compositions of peptides having low solubility in physiological medium SI0984788T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP97108593A EP0880968A1 (de) 1997-05-28 1997-05-28 In physiologischem Medium schwerlösliche pharmazeutische Peptidezusammensetzungen
EP97121246A EP0880969A1 (de) 1997-05-28 1997-12-03 Im physiologischem Medium schwerlösliche pharmazeutische Peptidezusammensetzungen
EP98930729A EP0984788B1 (de) 1997-05-28 1998-05-26 Pharmazeutische zubereitung enthaltend peptide mit geringer löslichkeit in physiologischem medium
PCT/EP1998/003079 WO1998053844A1 (en) 1997-05-28 1998-05-26 Pharmaceutical compostions of peptides having low solubility in physiological medium

Publications (1)

Publication Number Publication Date
SI0984788T1 true SI0984788T1 (en) 2004-02-29

Family

ID=26145485

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9830555T SI0984788T1 (en) 1997-05-28 1998-05-26 Pharmaceutical compositions of peptides having low solubility in physiological medium

Country Status (27)

Country Link
US (1) US6331520B1 (de)
EP (2) EP0880969A1 (de)
JP (1) JP2002502384A (de)
KR (1) KR100552546B1 (de)
CN (1) CN1159062C (de)
AR (1) AR012868A1 (de)
AT (1) ATE252909T1 (de)
AU (1) AU743152B2 (de)
BG (1) BG64668B1 (de)
BR (1) BR9809708A (de)
CA (1) CA2291765A1 (de)
CZ (1) CZ298825B6 (de)
DE (1) DE69819322T2 (de)
DK (1) DK0984788T3 (de)
EA (1) EA002227B1 (de)
EE (1) EE04001B1 (de)
ES (1) ES2210772T3 (de)
HK (1) HK1029928A1 (de)
IL (2) IL133176A0 (de)
NO (1) NO323697B1 (de)
NZ (1) NZ500777A (de)
PL (1) PL192647B1 (de)
PT (1) PT984788E (de)
SI (1) SI0984788T1 (de)
SK (1) SK284640B6 (de)
TR (1) TR199902865T2 (de)
WO (1) WO1998053844A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8343186B2 (en) 2004-04-06 2013-01-01 Arthrex, Inc. Fully threaded suture anchor with transverse anchor pin
EP1064934A1 (de) 1999-06-30 2001-01-03 Applied Research Systems ARS Holding N.V. Gefriergetrocknete GRF-enthaltende Arzneimittel
US20020061838A1 (en) * 2000-05-17 2002-05-23 Barton Holmquist Peptide pharmaceutical formulations
US20040229334A1 (en) * 2003-05-15 2004-11-18 Mendoza Christine B. Process for manufacture of nematode-extracted anticoagulant protein (NAP)
EP2142207A4 (de) * 2007-04-04 2013-01-16 Theratechnologies Inc Pharmazeutische formulierungen von ghrh-molekülen
JP6224586B2 (ja) 2012-07-10 2017-11-01 武田薬品工業株式会社 注射用製剤
US9107853B2 (en) 2012-10-12 2015-08-18 L'oreal S.A. Compositions containing phenolic compounds and hydrotropes for cosmetic use
JP6295261B2 (ja) * 2012-10-12 2018-03-14 ロレアル 少なくとも一種のヒドロトロープ及び少なくとも一種の活性化合物を含む化粧品組成物
US9018177B2 (en) 2012-10-12 2015-04-28 L'oreal S.A. Cosmetic compositions for increasing bioavailability of the active compounds baicalin and/or vitamin C
US9072919B2 (en) 2012-10-12 2015-07-07 L'oreal S.A. Synergistic antioxidant cosmetic compositions containing at least one of baicalin and taxifolin, at least one of caffeine and nicotinamide, at least one of vitamin C and resveratrol and ferulic acid
US9023826B2 (en) 2012-10-12 2015-05-05 L'oreal S.A. Compositions containing adenosine and the hydrotropes caffeine and nicotinamide for cosmetic use
US9669242B2 (en) 2013-07-01 2017-06-06 L'oreal Compositions containing at least two phenolic compounds, a lipid-soluble antioxidant and at least one hydrotrope for cosmetic use
JP6634758B2 (ja) * 2015-09-25 2020-01-22 ニプロ株式会社 液体組成物及び凍結乾燥製剤
JP7030720B2 (ja) 2016-02-16 2022-03-07 ストロングブリッジ ダブリン リミテッド 先端巨大症、先端巨大症がん、sst-r5発現腫瘍、2型糖尿病、高血糖症、及びホルモン関連腫瘍の治療において使用するための、生理学的条件において難溶性であるベルドレオチド

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4563352A (en) * 1982-10-04 1986-01-07 The Salk Institute For Biological Studies Human pancreatic GRF
US4935491A (en) * 1987-08-24 1990-06-19 Board Of Regents, The University Of Texas System Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine
EP0374120A3 (de) * 1988-12-13 1991-07-31 Monsanto Company Zusammensetzung mit kontrollierter Wirkstoffabgabe von Polypeptiden
DE69019534T2 (de) * 1989-12-21 1995-09-21 Novo Nordisk As Insulinzubereitungen, die nikotinsäure oder nikotinamid enthalten.
AU653026B2 (en) * 1991-06-07 1994-09-15 Teikoku Seiyaku Kabushiki Kaisha Physiologically active polypeptide-containing pharmaceutical composition
US5487898A (en) * 1991-08-26 1996-01-30 Abbott Laboratories Compositions and method for the sublingual or buccal administration therapeutic agents
ES2153362T3 (es) * 1991-08-26 2001-03-01 Abbott Lab Composiciones y procedimientos de administracion sublingual o bucal de agentes terapeuticos.
US5446025A (en) * 1992-06-12 1995-08-29 Abbott Laboratories Formulations and method of the percutaneous administration of leuprolide
CA2123144A1 (en) * 1993-05-10 1994-11-11 David Bodmer Stabilisation of pharmacologically active compounds in sustained release compositions
TW280770B (de) * 1993-10-15 1996-07-11 Takeda Pharm Industry Co Ltd
WO1996010417A1 (en) * 1994-10-04 1996-04-11 Novo Nordisk A/S PREPARATIONS CONTAINING AspB28 HUMAN INSULIN AND NICOTINAMIDE
KR100236393B1 (ko) * 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제

Also Published As

Publication number Publication date
ATE252909T1 (de) 2003-11-15
DE69819322D1 (de) 2003-12-04
US6331520B1 (en) 2001-12-18
CZ298825B6 (cs) 2008-02-20
DK0984788T3 (da) 2004-03-08
AU8106298A (en) 1998-12-30
EE04001B1 (et) 2003-04-15
JP2002502384A (ja) 2002-01-22
EP0984788A1 (de) 2000-03-15
AR012868A1 (es) 2000-11-22
CZ423199A3 (cs) 2000-05-17
EE9900545A (et) 2000-06-15
EP0880969A1 (de) 1998-12-02
CN1159062C (zh) 2004-07-28
WO1998053844A1 (en) 1998-12-03
NO995763D0 (no) 1999-11-24
AU743152B2 (en) 2002-01-17
TR199902865T2 (xx) 2000-05-22
EA002227B1 (ru) 2002-02-28
ES2210772T3 (es) 2004-07-01
PL192647B1 (pl) 2006-11-30
BR9809708A (pt) 2000-07-11
PT984788E (pt) 2004-01-30
SK159799A3 (en) 2000-07-11
NO323697B1 (no) 2007-06-25
NZ500777A (en) 2001-09-28
EA199901089A1 (ru) 2000-06-26
SK284640B6 (sk) 2005-08-04
HK1029928A1 (en) 2001-04-20
PL336982A1 (en) 2000-07-31
BG64668B1 (bg) 2005-11-30
CN1263469A (zh) 2000-08-16
NO995763L (no) 1999-11-24
IL133176A0 (en) 2001-03-19
EP0984788B1 (de) 2003-10-29
CA2291765A1 (en) 1998-12-03
BG103884A (en) 2000-07-31
DE69819322T2 (de) 2004-07-29
IL133176A (en) 2006-08-01
KR20010012253A (ko) 2001-02-15
KR100552546B1 (ko) 2006-02-14

Similar Documents

Publication Publication Date Title
HUP0100178A3 (en) Tetrahydro-naphtiridinyl-imidazolydinyl-carboxylic acid derivatives and pharmaceutical compositions thereof
HUP0003761A3 (en) Substituted alkanohydroxamic acids and pharmaceutical compositions containing them
HUP0100149A3 (en) Antipicornaviral peptide derivatives pharmaceutical compositions comprising thereof and their use
HUS1200028I1 (hu) 4"-Szubsztituált-9-dezoxo-9a-aza-9a-homoeritromicin-származékok és ezeket tartalmazó gyógyszerek
EP0950665A4 (de) Veränderte physiologisch aktive proteine und medizinische verbindungen, die diese beinhalten
IL135177A0 (en) Amidocarboxylic acid derivatives and pharmaceutical compositions containing the same
HUP9701018A3 (en) Xantine derivatives having (omega-amino)-hydroxyalkynyl side-chain and pharmaceutical compositions containing them
HUP0001269A3 (en) 2-oxo-1-azetidine sulfonic acid derivatives and combined pharmaceutical compositions thereof
IL114925A0 (en) Glycinamide derivatives their preparation and pharmaceutical compositions containing them
HUP0002510A3 (en) Tetrazole derivatives and pharmaceutical compositions containing them
IL133176A0 (en) Pharmaceutical compositions of peptides having low solubility in physiological medium
HU9800147D0 (en) Isoxasol-and crotonoil-amide derivatives and pharmaceutical and diagnostical compositions containing them
IL124661A0 (en) 5'-Deoxy-cytidine derivatives their preparation and pharmaceutical compositions containing them
HUP0002331A3 (en) 20-aralkyl-5alpha-pregnane derivatives and pharmaceutical compositions thereof
HUP0101701A3 (en) Substituted betha-alanines and pharmaceutical compositions comprising them
ZA9811655B (en) Phenylaminoalkylcarboxylic acid derivatives and pharmaceutical compositions comprising the same
HUP0004223A3 (en) 4-oxo-butynic acids and pharmaceutical composition containing them as active agent
IL125908A0 (en) Peptides and pharmaceutical compositions comprising same
IL131266A0 (en) Peptides and pharmaceutical compositions comprising same
ZA982952B (en) Pseudo-peptide compounds their preparation and use in pharmaceutical formulations
HUP0002118A3 (en) Pharmaceutical compositions of peptides having low solubility in physiological medium
ZA984469B (en) Pharmaceutical compositions of peptides having low solubility of physiological medium
HUP0500956A2 (en) Oxapenem-3-carboxylic acids and pharmaceutical compositions containing them
HUP0102705A3 (en) Alpha-amino acid phenyl ester derivatives and their use and pharmaceutical compositions comprising them
IL123429A0 (en) Peptides and pharmaceutical compositions comprising same